VERA Stock: Insider Activity, Filings & Research

Vera Therapeutics, Inc. (VERA) — Drillr’s hub for VERA insider activity, SEC filings, earnings signals and AI research. Over the trailing 3 months, VERA insiders filed 0 open-market buys and 5 sales (SEC Form 4).

Sentiment

0/100

Buys (3m)

Sells (3m)

Net (3m)

-$1.7M

Insider trades by month Buys Sells

Jun

Nov

Dec

Feb

Apr

May

Context3-month price -21.1%Institutions accumulating (13F)

Date	Insider	Type	Shares	Price
May 26, 2026	ENRIGHT PATRICK Gdirector	Grant	17,084	$34.35
May 26, 2026	Morrison Scott Wdirector	Grant	17,084	$34.35
May 26, 2026	Cheng Andrewdirector	Grant	17,084	$34.35
May 26, 2026	SEIDENBERG BETH Cdirector	Grant	17,084	$34.35
May 26, 2026	Oliger Christy J.director	Grant	17,084	$34.35
May 26, 2026	Meyers James Rdirector	Grant	17,084	$34.35
May 26, 2026	Hall Kimballdirector	Grant	17,084	$34.35
May 26, 2026	MORRISSEY MICHAELdirector	Grant	17,084	$34.35
May 13, 2026	Fordyce Marshalldirector, officer: PRESIDENT AND CEO	Sell	4,281	$37.09
May 13, 2026	Fordyce Marshalldirector, officer: PRESIDENT AND CEO	Sell	14,219	$36.64
Apr 15, 2026	Fordyce Marshalldirector, officer: PRESIDENT AND CEO	Sell	14,130	$43.66
Apr 15, 2026	Fordyce Marshalldirector, officer: PRESIDENT AND CEO	Sell	7,921	$44.58
Apr 15, 2026	Fordyce Marshalldirector, officer: PRESIDENT AND CEO	Sell	900	$45.51
Mar 25, 2026	Wright-Mitchell Janeofficer: Chief Legal Officer	Grant	42,403	—
Mar 25, 2026	Wright-Mitchell Janeofficer: Chief Legal Officer	Grant	56,850	$40.73

Source: VERA SEC Form 4 filings, latest May 26, 2026. For informational purposes only — not investment advice.

Overview

Vera Therapeutics, Inc. (NASDAQ:VERA) is a clinical-stage biotechnology company founded in 2016 and headquartered in Brisbane, California. Originally incorporated as Trucode Gene Repair, Inc., the company changed its name to Vera Therapeutics in April 2020 and went public in May 2021. The company focuses on developing and commercializing treatments for patients with serious immunological diseases, with its primary emphasis on rare kidney diseases and viral infections that affect immunocompromised patients.

Business

Vera Therapeutics operates in the biotechnology sector, specifically focusing on developing therapeutic treatments for immunological diseases. The company's core business revolves around advancing two main drug candidates through clinical trials. The company's lead product candidate is atacicept, a fusion protein that patients self-administer through subcutaneous injection. Atacicept is currently in Phase IIb clinical trials for treating immunoglobulin A nephropathy (IgA nephropathy), a kidney disease that occurs when the antibody immunoglobulin A builds up in the kidneys, causing inflammation and potentially leading to kidney failure. IgA nephropathy is the most common form of glomerulonephritis worldwide and represents a significant unmet medical need, as there are limited treatment options available for patients with this progressive kidney disease. The company's second product candidate is MAU868, a monoclonal antibody designed to treat BK viremia infections. BK virus is a common polyomavirus that typically remains dormant in healthy individuals but can cause serious complications in immunocompromised patients, particularly kidney transplant recipients. When the virus reactivates, it can lead to BK viremia (virus in the blood) and potentially BK nephropathy, which can result in kidney transplant loss. MAU868 is currently undergoing Phase 2 clinical trials. Both of Vera's drug candidates target diseases with limited treatment options, positioning the company in specialized therapeutic areas where successful drug development could address significant unmet medical needs in nephrology and transplant medicine.

Revenue model

As a clinical-stage biotechnology company, Vera Therapeutics does not currently generate meaningful revenue from product sales. The company's financial statements show minimal revenue (less than $2 million in 2023, zero in most recent quarters), which likely comes from research collaborations or licensing arrangements rather than commercial product sales. Vera's business model is typical of early-stage biotech companies: the company raises capital through equity financing and uses these funds to advance its drug candidates through clinical trials toward regulatory approval and eventual commercialization. The company's path to profitability depends on successfully completing clinical trials, obtaining regulatory approval from agencies like the FDA, and then either commercializing the drugs directly or partnering with larger pharmaceutical companies for distribution and sales. Several factors could significantly impact Vera's future margins and commercial success. Positive clinical trial results for atacicept or MAU868 would likely increase the company's valuation and partnership opportunities, while negative results could severely impact funding prospects. The competitive landscape in nephrology and transplant medicine could affect pricing power, though both target indications represent areas with limited treatment options. Regulatory approval timelines and requirements will directly impact development costs and time to market. Additionally, the company's ability to secure favorable partnership deals with larger pharmaceutical companies could determine whether it captures the full commercial value of its products or shares revenue through licensing arrangements. The biotechnology sector is inherently high-risk, with the majority of drug candidates failing during clinical development. However, successful drugs in rare disease areas often command premium pricing due to limited competition and high unmet medical need.

Competitive moat

Vera Therapeutics operates in a competitive biotechnology landscape with limited traditional moats. The company's primary competitive advantages stem from its clinical-stage assets and the specialized nature of its target diseases rather than sustainable structural advantages. The company's strongest position lies in its advanced clinical development of atacicept for IgA nephropathy. Being in Phase IIb trials provides Vera with a timing advantage over competitors who may be earlier in development for the same indication. IgA nephropathy represents a significant unmet medical need with limited approved treatments, potentially providing market exclusivity for successful therapies. However, this advantage is temporary and depends entirely on successful trial outcomes. Vera's intellectual property portfolio around its drug candidates provides some protection, but patents in biotechnology are often subject to challenges and have finite terms. The company does not possess manufacturing advantages, distribution networks, or other traditional competitive moats that characterize more established businesses. The primary competitive threats come from other biotechnology companies developing treatments for the same indications, large pharmaceutical companies with greater resources that could accelerate competing programs, and the inherent risk that clinical trials may fail. Additionally, the specialized nature of Vera's target markets means that even successful drug development may result in relatively small addressable markets compared to broader therapeutic areas. The company's competitive position is fundamentally dependent on clinical execution and regulatory success rather than sustainable business advantages. While the specialized nature of its target diseases provides some protection from competition, this same specialization limits the ultimate market size and commercial potential.

Risks & safety

Vera Therapeutics presents a mixed margin of safety profile typical of clinical-stage biotechnology companies, with strong liquidity but significant execution risks. • Liquidity and Solvency: The company maintains a strong cash position with $55.1 million in cash and short-term investments as of Q1 2025, down from $92.6 million at year-end 2024. With quarterly cash burn of approximately $54 million, the current cash runway extends roughly 4-5 quarters without additional financing. • Debt and Financial Leverage: Vera maintains low debt levels with a debt-to-equity ratio of 0.10, indicating minimal financial leverage risk. Current ratio of 27.7 demonstrates excellent short-term liquidity coverage. • Valuation Metrics: Traditional valuation metrics are not meaningful for a pre-revenue biotech company. The enterprise value reflects the market's assessment of clinical trial success probability and commercial potential. • Operational Burn: Operating cash flow burn of $54.4 million in Q1 2025 represents the primary financial risk, requiring either successful clinical milestones to attract additional funding or eventual revenue generation. • Clinical Risk: The primary safety concern lies in clinical execution risk rather than financial metrics, as failed trials could significantly impact the company's ability to raise additional capital and continue operations.

Recent development

Based on the available financial data, Vera Therapeutics has been primarily focused on advancing its two key clinical programs over recent years. The company has maintained consistent investment in research and development, as evidenced by steady cash burn rates and continued clinical trial progression. The company's strategic focus has remained centered on advancing atacicept through Phase IIb trials for IgA nephropathy, representing the most advanced and potentially valuable asset in its pipeline. Simultaneously, Vera has continued developing MAU868 for BK viremia infections in Phase 2 trials, maintaining a dual-track approach to drug development. From a financial perspective, the company has successfully managed its capital structure, maintaining low debt levels while funding operations through equity financing. The significant increase in cash and current assets between 2023 and 2024 (from approximately $172 million to $651 million in current assets) suggests the company completed a substantial financing round, providing runway for continued clinical development. The company's operational focus appears to have intensified, with increased quarterly burn rates in recent periods reflecting more active clinical trial activities. This suggests both programs may be in more resource-intensive phases of development, potentially indicating progress toward key clinical milestones or trial readouts.

VERA company profile · for informational purposes only — not investment advice.

Track VERA with Drillr

SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.

Try Drillr for free